Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Med 2022 | SCUlpTOR: CYP-004 in osteoarthritis

Ross Macdonald, PhD, Cynata Therapeutics, Melbourne, Australia, discusses the Phase III SCUlpTOR trial (ACTRN12620000870954) assessing CYP-004, a novel mesenchymal stem cell (MSCs)-based cell therapy for patients with osteoarthritis. Whilst previous studies investigating autologous stem cell therapies have shown promise, there is an unmet need for curative therapies. The randomized double blind trial will assess the investigational therapy in 440 patients with degenerative osteoarthritis. The interview was conducted during Meeting on the Mediterranean 2022.